List of Bafiertam drug patents
Bafiertam is owned by Banner Life Sciences.
Bafiertam contains Monomethyl Fumarate.
Bafiertam has a total of 19 drug patents out of which 0 drug patents have expired.
Bafiertam was authorised for market use on 28 April, 2020.
Bafiertam is available in capsule, delayed release;oral dosage forms.
Bafiertam can be used as method of treating multiple sclerosis.
The generics of Bafiertam are possible to be released after 14 August, 2035.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10105335 | BANNER LIFE SCIENCES | Fumarate ester dosage forms |
Feb, 2035
(12 years from now) | |
| US9820960 | BANNER LIFE SCIENCES | Fumarate ester pharmaceutical compositions |
Feb, 2035
(12 years from now) | |
| US9517209 | BANNER LIFE SCIENCES | Fumarate ester pharmaceutical compositions |
Feb, 2035
(12 years from now) | |
| US9511043 | BANNER LIFE SCIENCES | Fumarate ester pharmaceutical compositions |
Feb, 2035
(12 years from now) | |
| US9326965 | BANNER LIFE SCIENCES | Controlled release fumarate esters |
Feb, 2035
(12 years from now) | |
| US9814692 | BANNER LIFE SCIENCES | Fumarate ester dosage forms |
Feb, 2035
(12 years from now) | |
| US9636318 | BANNER LIFE SCIENCES | Fumarate ester dosage forms |
Feb, 2035
(12 years from now) | |
| US9814691 | BANNER LIFE SCIENCES | Fumarate ester pharmaceutical compositions |
Feb, 2035
(12 years from now) | |
| US10105336 | BANNER LIFE SCIENCES | Fumarate ester pharmaceutical compositions |
Feb, 2035
(12 years from now) | |
| US9820961 | BANNER LIFE SCIENCES | Fumarate ester dosage forms |
Feb, 2035
(12 years from now) | |
| US10098863 | BANNER LIFE SCIENCES | Fumarate esters |
Feb, 2035
(12 years from now) | |
| US9566259 | BANNER LIFE SCIENCES | Fumarate ester dosage forms |
Feb, 2035
(12 years from now) | |
| US9636319 | BANNER LIFE SCIENCES | Fumarate ester dosage forms |
Feb, 2035
(12 years from now) | |
| US10105337 | BANNER LIFE SCIENCES | Fumarate ester pharmaceutical compositions |
Feb, 2035
(12 years from now) | |
| US9326947 | BANNER LIFE SCIENCES | Controlled release fumarate esters |
Feb, 2035
(12 years from now) | |
| US10918616 | BANNER LIFE SCIENCES | Fumarate ester pharmaceutical compositions |
Jun, 2035
(12 years from now) | |
| US10918617 | BANNER LIFE SCIENCES | Fumarate ester pharmaceutical compositions |
Aug, 2035
(12 years from now) | |
| US10918615 | BANNER LIFE SCIENCES | Fumarate esters |
Aug, 2035
(12 years from now) | |
| US10945985 | BANNER LIFE SCIENCES | Fumarate ester dosage forms |
Aug, 2035
(12 years from now) | |
Drugs and Companies using MONOMETHYL FUMARATE ingredient
Market Authorisation Date: 28 April, 2020
Treatment: Method of treating multiple sclerosis
Dosage: CAPSULE, DELAYED RELEASE;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic